NCT07268820 Heartburn, Gastroesophageal Reflux Disease
| NCT ID | NCT07268820 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Incheon St.Mary's Hospital |
| Condition | GERD |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-07-07 |
| Primary Completion | 2026-05-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 160 participants in total. It began in 2025-07-07 with a primary completion date of 2026-05-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation. GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life. This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).
Eligibility Criteria
Inclusion Criteria: 1. Korean adults aged 19 years or older as of the date of written consent 2. Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD) 3. Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1) 4. Those who voluntarily decided to participate and provide written informed consent Exclusion Criteria: 1. Those who cannot undergo upper gastrointestinal endoscopy (EGD) 2. Individuals with a history of drug or alcohol abuse (within the past year) 3. Individuals who have received other investigational products within one month prior to the screening visit (Visit 1) 4. In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07268820 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying GERD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07268820 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07268820 currently recruiting?
Yes, NCT07268820 is actively recruiting participants. Contact the research team at gastro@catholic.ac.kr for enrollment information.
Where is the NCT07268820 trial being conducted?
This trial is being conducted at Ansan, South Korea, Busan, South Korea, Chilgok, South Korea, Chuncheon, South Korea and 6 additional locations.
Who is sponsoring the NCT07268820 clinical trial?
NCT07268820 is sponsored by Incheon St.Mary's Hospital. The trial plans to enroll 160 participants.